Items where authors include "Verrill, M."
![[up]](/style/images/multi_up.png)
Up a levelArticle
Velikova, G. orcid.org/0000-0003-1899-5942, Morden, J.P., Haviland, J.S. et al. (14 more authors) (2023) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 24 (12). pp. 1359-1374. ISSN 1470-2045
El Badri, S., Tahir, B., Balachandran, K. et al. (18 more authors) (2021) Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer : a real-world multicentre UK study. The Breast, 60. pp. 199-205. ISSN 0960-9776
Verrill, M., Wardley, A.M., Retzler, J. orcid.org/0000-0002-0008-3104 et al. (6 more authors) (2020) Health-related quality of life and work productivity in UK patients with HER2-positive breast cancer: a cross-sectional study evaluating the relationships between disease and treatment stage. Health and Quality of Life Outcomes, 18. 353. ISSN 1477-7525
Cameron, D., Morden, J.P., Canney, P. et al. (21 more authors) (2017) Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology, 18 (7). pp. 929-945. ISSN 1470-2045
Serin, D., Verrill, M., Jones, A. et al. (6 more authors) (2005) Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. British Journal of Cancer, 92 (11). pp. 1989-1996. ISSN 0007-0920
Proceedings Paper
El Badri, S., Tahir, B. orcid.org/0000-0003-0531-3519, Balachandran, K. et al. (16 more authors) (2021) 245P Palbociclib combined with aromatase inhibitors (AIs) in women ≥75 years with oestrogen receptor positive (ER+ve), human epidermal growth factor receptor 2 negative (HER2-ve) advanced breast cancer: a real-world multicentre UK study. In: Annals of Oncology. ESMO Congress 2021, 16-21 Sep 2021, Virtual conference. Elsevier BV , S466-S466.